<DOC>
	<DOCNO>NCT02986724</DOCNO>
	<brief_summary>The purpose non-interventional study ( NIS ) study assess knowledge routine use Entyvio inflammatory bowel disease therapy , particularly use participant CD UC naive biologics .</brief_summary>
	<brief_title>A Study Observe Safety Efficacy Vedolizumab Biologically Naive Participants Wtih Ulcerative Colitis ( UC ) CrohnÂ´s Disease ( CD )</brief_title>
	<detailed_description>The drug test prospective , observational study call vedolizumab . Vedolizumab ( Entyvio ) use treat people CD UC . This study look routine use vedolizumab inflammatory bowel disease therapy participant CD UC receive biologic treatment . The study enroll approximately 150 participant . All participant enrol belong one observational group : Vedolizumab . Participants take vedolizumab per physician 's prescription routine clinical practice observe . This multi-centre trial conduct Austria . The overall time participate study 2 year . Participant take vedolizumab routine clinical practice make multiple visit clinic Baseline , Week 20 52 . Once participant switch subsequent biologic treatment upon fail treatment vedolizumab , switch date consider new baseline follow visit Week 20 52 .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<criteria>Inclusion Criteria 1 Initiating vedolizumab moderately severely active UC CD . Exclusion Criteria 1 . Participant enrolled clinical trial treatment UC CD manage protocol , 2 . Prior treatment biologic agent , 3 . Any reason , Investigator 's opinion , make participant unsuitable participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>